Purpose—Symptomatic intracranial hemorrhage (sICH) is the most feared complication of
intravenous thrombolytic therapy in acute ischemic stroke. Treatment of sICH is based on …

Importance Intravenous thrombolysis remains the mainstay treatment for acute ischemic
stroke. One of the most feared complications of the treatment is thrombolysis-related …

Background Symptomatic intracerebral hemorrhage (sICH) is the most devastating
complication of thrombolytic therapy for acute stroke. It is not clear whether patients with …

Background: Symptomatic intracranial hemorrhage (SICH) is a devastating complication of
intravenous thrombolysis treatment that is associated with high mortality. Clinical trials …

After publication of the results of the National Institute of Neurological Disorders and Stroke
study, the application of intravenous thrombolysis for ischemic stroke was launched and has …

Purpose—To critically review and evaluate the science behind individual eligibility criteria
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …

Background Intravenous thrombolysis with alteplase is the only approved treatment for acute
ischemic stroke, but its efficacy and safety when administered more than 3 hours after the …

Background and Purpose—Symptomatic intracerebral hemorrhage (SICH) is a serious
complication in patients with acute ischemic stroke treated with intravenous thrombolysis …

Background: Symptomatic intracerebral hemorrhage (SICH) following thrombolytic therapy
for acute ischemic stroke is associated with a high rate of morbidity and mortality …

Importance Treatments for symptomatic intracerebral hemorrhage (sICH) are based on
expert opinion, with limited data available on efficacy. Objective To better understand the …